Carmichael Hill & Associates Inc. purchased a new stake in Eli Lilly and Co (NYSE:LLY) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 2,976 shares of the company’s stock, valued at approximately $251,000.

Other hedge funds also recently bought and sold shares of the company. Airain ltd acquired a new stake in shares of Eli Lilly and during the 2nd quarter worth about $567,000. Buckingham Asset Management LLC raised its position in shares of Eli Lilly and by 21.3% during the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after acquiring an additional 568 shares in the last quarter. BSW Wealth Partners raised its position in shares of Eli Lilly and by 0.6% during the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after acquiring an additional 27 shares in the last quarter. Mirador Capital Partners LP raised its position in shares of Eli Lilly and by 5.3% during the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock worth $1,011,000 after acquiring an additional 619 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. raised its position in shares of Eli Lilly and by 166.7% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock worth $36,818,000 after acquiring an additional 269,038 shares in the last quarter. 76.45% of the stock is currently owned by institutional investors.

In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total value of $72,981.00. Following the transaction, the insider now directly owns 4,130 shares in the company, valued at approximately $334,901.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeffrey N. Simmons sold 9,625 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the completion of the transaction, the senior vice president now owns 152,120 shares in the company, valued at $12,339,974.40. The disclosure for this sale can be found here. Insiders sold a total of 259,610 shares of company stock worth $22,727,406 over the last quarter. Company insiders own 0.20% of the company’s stock.

Several equities research analysts have recently weighed in on LLY shares. Piper Jaffray Companies reissued a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research report on Friday, October 13th. Berenberg Bank reissued a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 target price on the stock in a research report on Thursday, October 26th. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and raised their target price for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Jefferies Group set a $100.00 target price on Eli Lilly and and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $92.02.

Eli Lilly and Co (LLY) opened at $76.23 on Friday. The stock has a market capitalization of $83,940.00, a P/E ratio of -381.15, a P/E/G ratio of 1.41 and a beta of 0.23. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Co has a 12 month low of $73.69 and a 12 month high of $89.09.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.95 EPS. analysts expect that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a dividend yield of 2.95%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is -1,040.00%.

TRADEMARK VIOLATION NOTICE: “Carmichael Hill & Associates Inc. Purchases New Stake in Eli Lilly and Co (LLY)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/02/10/carmichael-hill-associates-inc-purchases-new-stake-in-eli-lilly-and-co-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.